Objectives: Neisseria gonorrhoeae antimicrobial resistance (AMR) is a global problem heightened by emerging resistance to ceftriaxone. Appropriate molecular typing methods are important for understanding the emergence and spread of N. gonorrhoeae AMR. We report on the development, validation and testing of a Sequenom MassARRAY iPLEX method for multilocus sequence typing (MLST)-style genotyping of N. gonorrhoeae isolates.
Introduction
Increasing antimicrobial resistance (AMR) in Neisseria gonorrhoeae is a serious global problem and is exemplified by the fact that resistance to ceftriaxone is now emerging. 1 Molecular typing methods are critical to understanding the genetic relatedness, diversity and spread of N. gonorrhoeae AMR for disease prevention and control. A number of molecular typing methods are available for N. gonorrhoeae AMR studies; 2 however, it is multilocus sequence typing (MLST), which targets several gonococcal housekeeping genes, that is ideally suited for long-term or global epidemiological (macroepidemiology) investigations, including the evolutionary relationship between resistant strains. 2 For example, the application of MLST to investigate the emergence of ceftriaxone resistance in N. gonorrhoeae has so far identified two key sequence types (STs), namely ST7363 and ST1901, both of which have been associated with the mosaic penicillin-binding protein 2 (PBP2) sequence that is considered a pivotal building block for ceftriaxone resistance. 3, 4 Gonococci of ST1901 and ST7363 harbouring the mosaic PBP2 sequence were first reported in Japan and have since become established as successful clones globally. 1 A major limitation of MLST is that it requires DNA sequencing of seven housekeeping genes and is thus costly and timeconsuming. To circumvent this problem, our laboratory recently developed a single nucleotide polymorphism (SNP)-based method, targeting informative SNPs in the same gonococcal MLST housekeeping genes. The method is able to distinguish the majority of known gonococcal MLST types based on a 14 SNP profile and achieved this at 30% of the cost of traditional MLST. 5 In Australia, we are now embarking on a large-scale national study of N. gonorrhoeae AMR: the Gonorrhoea Resistance Assessment by Nucleic Acid Detection (GRAND) study. One of the aims of this project is to better understand the transmission and spread of N. gonorrhoeae AMR in Australia; hence, we will be utilizing the SNP-based MLST approach. As we will potentially be testing several thousand isolates, we have endeavoured to make further improvements, in terms of workload and testing costs, in SNP characterization. The aims of this study were to adapt the 14 SNP method to the Sequenom MassARRAY iPLEX platform 6 and then apply it to isolates referred for AMR testing in the state of Queensland over a 6 month period.
Materials and methods

Validation (control) isolates
Twenty-four N. gonorrhoeae control isolates were used to validate the MassARRAY iPLEX method. These isolates were previously tested by SYBR Green-based real-time PCR assays and collectively were representative of each of the 14 SNPs (see Table S1 , available as Supplementary data at JAC Online). 5 The isolates were predominantly from Australia (n ¼ 20) and collected in the time period 2004 -10.
Test isolates
The test isolates comprised all N. gonorrhoeae isolates (n¼397) that were referred to the Queensland Health Forensic and Scientific Services laboratory in the first half of 2012. The isolates were originally identified and subjected to antibiotic susceptibility testing using standard bacterial culture-based methods. 7 These isolates also form part of a broader Australia-wide collection of isolates collected as part of our ongoing GRAND study. In the initial phase of the GRAND study, these isolates were tested by real-time PCR methods targeting the gonococcal opa and cppB genes and the porA pseudogene to confirm organism identity. All 397 isolates were considered to represent N. gonorrhoeae on the basis of the real-time PCR data. MICs were determined by agar dilution as per the method of the Australian Gonococcal Surveillance Programme (AGSP). 8, 9 Susceptibility categories for penicillin were defined as susceptible (S; MIC ≤0.03 mg/L), less susceptible (LS; MIC 0.06 -0.5 mg/L) or resistant (R; MIC ≥1 mg/L). Resistance was classified as either chromosomally mediated resistance to penicillin (CMRP) or as being due to penicillinase-producing N. gonorrhoea (PPNG). MICs for ciprofloxacin-S, -LS or -R isolates were ≤0.03, 0.06 -0.5 and ≥1 mg/L, whereas the MICs for isolates susceptible to and showing decreased susceptibility (DS) to ceftriaxone were ≤0.03 and 0.06 -0.125 mg/L, respectively. For isolates S or R to azithromycin the MICs were ≤0.5 and ≥1 mg/L, respectively, while for isolates S or R to spectinomycin the corresponding MICs were ≤64 and .64 mg/L. Tetracycline-resistant N. gonorrhoea (TRNG) and non-TRNG had tetracycline MICs of ≥16 and ≤8 mg/L, respectively.
SNP MLST iPLEX MassARRAY (iPLEX14SNP) assay
In this study, an iPLEX MassARRAY method (iPLEX14SNP) was developed targeting 14 informative SNPs across six (abcZ, aroE, fumC, gdh, pdhC and pgm) of the seven gonococcal housekeeping genes that are commonly used for MLST investigations. 5 In brief, the iPLEX14SNP assay was an adaption to the Sequenom platform of a previous real-time PCR 14 SNP method described by our laboratory, which we showed could be used to individually distinguish 155 of 217 MLST types in the MLST database (database accessed on 20 June 2012), with a further 62 MLST types having overlapping 14 SNP profiles (between two and four MLST types with the same 14 SNP profile). 5 Amplification primers and extension primers (Tables 1 and 2 ) for each of the 14 SNPs in the iPLEX14SNP were N. gonorrhoeae SNP-based typing designed using the Assay Designer 4.0 software (Sequenom) and based on methods previously described. 10 All amplification primers commenced with the 5 ′ 10-mer tag (ACGTTGGATG) to ensure they fell outside the observed mass window.
The initial amplification PCR was performed on a conventional 96-well thermal cycler (Applied Biosystems, USA) using the Sequenom amplification kit. Amplification primers and associated concentrations are provided in Table 1 . Each PCR mix utilized a total volume of 10 mL including 2 mL of prepared isolate. The isolates were prepared as part of a previous study. 7 Briefly, a simple heat denaturation method previously described by our laboratory was used, whereby three to six colonies from a 24 h singlecolony subculture of each isolate were suspended in 1.0 mL of distilled water in a 1.5 mL tube and heated at 1008C for 8 min. 11 The cycling conditions were as previously described. 10 SNP detection by MassARRAY was performed as previously described, 10 using the PRO Reaction Kit (Sequenom) with an additional initial step prior to shrimp alkaline phosphatase (SAP) treatment involving the addition of 1.0 mL of Qiagen protease solution (stock: 1.07 AU/mL) to 5.0 mL of amplified DNA in a 384-well microtitre plate and incubation for 30 min at 558C followed by 5 min at 958C.
The SNP results were coded from 1 to 14 to generate a 14 SNP code as previously described.
5 The 14 SNP profiles were then interpreted using the data compiled from in silico analysis of the N. gonorrhoeae MLST database to provide predicted STs.
Results
Validation of N. gonorrhoeae iPLEX14SNP using control isolates
The iPLEX14SNP results for the 24 control isolates were 100% accurate; an SNP was identified for all 14 SNPs for all 24 isolates (336/336; SNP call rate ¼ 100%) and all SNPs identified by the iPLEX14SNP method were consistent with the known SNP results for these isolates based on previous real-time PCR testing. 7 
Test isolates
Results for all 397 test isolates are provided in Table S2 (available as Supplementary data at JAC Online) and the most common SNP profiles (n.5) are provided in Table 3 . For the 397 test isolates, the iPLEX14SNP call rate was 98.25% (5461/5558), with complete 14 SNP profiles obtained for 364 isolates. Using the iPLEX14SNP method, up to 384 isolates could be tested within 1 working day for less than Aus$10 per isolate.
Failed calls from 33 different isolates included 97 'no allele calls' (i.e. no extension product) and 2 mixed calls where more than one call was given for an SNP. The majority of the failed calls were associated with lower DNA loads as determined using the results of previous real-time PCR testing of these isolates. 7 Real-time PCR cycle threshold (Ct) values for isolates with failed SNP calls ranged between 18.08 and 41.78 with a mean of 28.4, whereas isolates with complete 14 SNP profiles exhibited Ct values ranging between 16.33 and 33 with a mean Ct value of 21 (MannWhitney U-test, P,0.001).
For isolates with complete SNP profiles (n¼364), 49 different 14 SNP profiles were observed. When used to predict ST results, based on the MLST database as previously described, 5 STs could be assigned for 34 (69%) of the 49 SNP profiles. STs could not be assigned for the remaining 14 SNP profiles for 15 isolates. These were considered to represent previously unrecognized STs and therefore were named 'new01' to 'new15' (see Table S2 , available as Supplementary data at JAC Online). Of the 34 profiles for which an ST was assigned, there were 11 profiles that matched more than one ST on the MLST database (Profiles 1, 2, 3, 6, 7, 14, 21, 26, 39, 40 and 41; Table S2 , available as Supplementary data at JAC Online); these represented MLST types that could not be distinguished by the 14 SNP profiles. 5 An example of the latter is Profile 1 (Tables  S2 and S3 , available as Supplementary data at JAC Online), for which the predicted ST profile was '7363/7832', indicating that the 14 SNP profile matches both ST7363 and ST7832.
The majority (280/364; 77%) of the isolates with complete SNP profiles were accounted for by 11 of the 49 different STs/ novel SNP profiles. These were 7363/7832 (n ¼ 60 isolates; 16.5%), 1584/8128/8145 (n ¼ 40; 11%), 1579/1896 (n ¼ 38; 10.4%), 9363 (n ¼ 33; 9%), 8775 (n ¼ 30; 8.2%), 1901/6814/ 9365 (n ¼ 21; 5.8%), 7359/7825/7826 (n ¼ 14; 3.8%), new05 (n ¼ 13; 3.6%), 1588 (n ¼ 11; 3%), new02 (n ¼ 10; 2.7%) and new03 (n¼ 10; 2.7%).
Resistance to most antibiotics was also dominated by certain STs/novel SNP profiles ( Figure 1 and Table S3, available Trembizki et al. (12) central (6) west (5) OS (1) 
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NQ (3) central (2) Continued N. gonorrhoeae SNP-based typing While isolates of the common STs/novel SNP profiles were typically found in multiple regions throughout Queensland, there was a marked difference in the prevalence of certain STs/novel SNP profiles. For example, ST8775 (n ¼ 30; all of which were TRNG) was mainly found in north Queensland (NQ) (29/30), with 1 isolate from south-east Queensland (SEQ). Similarly, the majority of isolates of ST1579/1896 (36/38; 95%) were found in SEQ, with only 1 isolate each being found in NQ and central Queensland.
Discussion
The overall aim of this study was to develop and validate a highthroughput method for MLST-style genotyping of N. gonorrhoeae isolates to assist in our ongoing surveillance studies of gonococcal AMR. Here, we adapted a previously described real-time PCR informative SNP-based typing method 5 to the Sequenom iPLEX platform. Overall, our results show that the technology is well suited for high-throughput typing of N. gonorrhoeae isolates. In particular, we found it can be used on heat-denatured isolates (removing the need for a commercial DNA extraction kit) and represented a considerable cost saving compared with other technologies. For our 397 test isolates, we estimate that classical DNA sequencing-based MLST would otherwise have cost approximately Aus$48 640 (Aus$120 per isolate) and that our previous real-time method would have cost Aus$13 498 (Aus$34 per isolate). 5 Using the iPLEX14SNP method, total testing costs were under Aus$4000 and the method will therefore be particularly beneficial for our ongoing studies, which will involve genotyping .2000 gonococcal isolates. In terms of instrument costs, the Sequenom platform is currently considerably more expensive than a typical real-time PCR thermocycler; however, the iPLEX technology may be otherwise accessible via numerous commercial biotechnology companies that now offer such services. In fact, for many of our ongoing studies, we are now performing the initial primary conventional PCR in our own laboratory and then shipping the PCR products to a commercial company for iPLEX processing.
Technical limitations of the iPLEX14SNP method included that complete 14 SNP profiles could not be obtained for 33 isolates. Based on our previous experience with iPLEX technology, we suspect that the majority of these problems were caused by lower DNA loads or sequence variation in the primer targets for some strains. Nevertheless, we believe these limitations are outweighed by the sheer throughput and cost savings associated with the system. Furthermore, any such failed calls can readily be retested using an alternative technology (e.g. DNA sequencing) if warranted. An additional limitation of the SNP method is that it does not have its own dedicated database and 'piggybacks' off the MLST site. Of note was that in this study there were 15 'new' SNP profiles that did not match with any known STs and a further 11 profiles that matched with more than one ST. However, as previously described, 5 the SNP method provides optimal discriminatory power compared with MLST (Simpson's index of diversity¼ 0.998) and is therefore a highly discriminatory method in its own right. Thus, the issue of matching STs may only be a problem where a study requires definitive MLST types, in which case the selected use of DNA sequencing could be used in conjunction with the SNP typing where warranted. It should also be noted that there are other MLST schemes available for N. 
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gonorrhoeae 2, 12 and that the SNP analysis could be extended to the multiplicity of commonly used MLST genes if required.
Among the 364 isolates with complete SNP profiles in this study, there were 49 different STs, with just 11 accounting for the majority (77%) of isolates. Of note was that resistance to certain antibiotics, particularly penicillin and tetracycline, was dominated by certain STs. This was most evident for CMRP, where 43 of 47 isolates were of either ST1579/1896 or ST1901/6814/9365 (Figure 1 ). While there were other isolates of these STs that were technically not resistant to penicillin (eight and seven isolates, respectively; Table 3 ), the majority were considered to be less susceptible. Overall, these findings are similar to those previously reported by Mavroidi et al. 13 in which the emergence and spread of ciprofloxacin resistance in Greece was shown by MLST to be attributed to a single successful clone (MLST type 1901) and hence further highlight the importance of clonal spread of AMR in N. gonorrhoeae. In this respect, our azithromycin resistance data are of some concern. While we observed only eight isolates (with complete SNP profiles) that were resistant to azithromycin, five of these were of ST9363 and all were found in SEQ. Thus, these data may be indicative of the establishment of an azithromycinresistant clone and are likely of clinical importance given azithromycin has only recently been introduced to the metropolitan regions of Australia as part of a dual-therapy regimen in combination with ceftriaxone.
In terms of ceftriaxone susceptibility, our results are consistent with previous data. ST1901 and ST7363 are well recognized as being associated with DS and resistance to ceftriaxone and have been reported in many regions throughout the world. 1 In our population, DS to ceftriaxone was observed for STs 1901/6814/ 9365 (n ¼ 7) and 7363/7832 (n ¼ 1) as well as one isolate of ST1579. Of interest, however, was that the bulk of our isolates of ST7363/7832 (59/60 isolates) did not exhibit DS to ceftriaxone. To our knowledge, this has not been reported previously. A possible reason for this may be that, rather than belonging to the actual ST7363, these 59 isolates could not be distinguished by the SNP-based protocol. It may also be that these isolates represent a variant of 7363 that lacks the mosaic PBP2 sequence, which is typically associated with ST7363 and considered one of the main building blocks towards ceftriaxone resistance. We are currently investigating these possibilities.
The fact that some STs predominated in certain geographical locations (e.g. 8775 in NQ and 1579/1896 in SEQ) is likely due to a combination of factors; there is a large geographical distance ( 2000 km) between SEQ and NQ and men who have sex with men account for the majority of gonorrhoea notifications in SEQ, whereas gonorrhoea in NQ is mainly among heterosexual indigenous populations. Thus, these STs likely represent established sexual networks isolated by both geographical distance and sexual orientation. Of further interest was that we observed 24 STs that were represented by only one isolate (Table S2 , available as Supplementary data at JAC Online) and only 2 of which were indicated to have been acquired from overseas. A recent study using the N. gonorrhoeae multiantigen sequence typing (NG-MAST) genotyping scheme to investigate gonococci in Portugal, 14 found that of 236 N. gonorrhoeae isolates there were 104 different NG-MAST types of which there were 69 types represented by a single isolate. The authors of that study raised questions over whether such heterogeneity represented a 'tip of the iceberg' scenario, whereby high numbers of gonorrhoea cases N. gonorrhoeae SNP-based typing must be going undiagnosed so as to maintain such high numbers of cases of unique NG-MAST types. While the proportion of unique STs in our study (24/364; 6.6%) was considerably lower than that observed by the Portuguese study (69/236; 29.2%), we were still somewhat surprised by the number of unique STs in our population given that: (i) our study used MLST, which is known to have considerably less discriminatory power than NG-MAST; (ii) considerable effort is made by the AGSP to ensure optimal numbers of isolates are collected from infected patients; and (iii) these unique STs were predominately found in the SEQ region, being the major metropolitan area of Queensland where AGSP activity is considered to be at its best. Questions remain over whether these STs represent established sexual networks that are being undersampled or whether they are simply new incursions into Queensland arriving via international or interstate travel. Such studies are ongoing. In summary, the iPLEX14SNP offers a high-throughput method for the MLST-style genotyping of N. gonorrhoeae. Here, we demonstrated this method can be used to generate a considerable amount of data at minimal cost and is therefore ideal for large-scale N. gonorrhoeae investigations. As part of our national GRAND study, we are now using the iPLEX14SNP method to test isolates collected from throughout Australia with a view to better understanding the emergence and spread of N. gonorrhoeae AMR in our country.
